Skip to main content

Table 1 Demographic and tumors characteristics of vaccinated patients by study

From: Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Demographic
Characteristics
Study
(Vaccine Arms)
  Phase II Trial Phase III Trial
Age   
Total 40 (100%) 40 (100%)
< 60 30 (75%) 25 (62.5%)
> 60 10 (25%) 15 (37.5%)
Race 34 (85%) 32 (80%)
White 34 (85%) 32 (80 %)
African Descendants 1 (2.5%) 6 (15%)
Other 5 (12.5%) 2 (5%)
Sex   
F 10 (25%) 27 (31.8%)
M 30 (75%) 57 (68.2%)
Stage   
IIIB 29 (72.5%) 56 (67.4%)
IV 11 (27.5%) 28 (32.6%)
Histological Type   
ADC 12 (30.8%) 32 (38.6%)
No ADC 27 (67.5%) 52 (61.4%)
ECOG   
0 9 (23%) 35 (40.4%)
1 24 (62%) 43 (50.6%)
2 6 (15%) 6 (7.9%)
\